EMEA-002431-PIP01-18
Key facts
| Invented name |
Alecensa
|
| Active substance |
Alectinib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0359/2018
|
| PIP number |
EMEA-002431-PIP01-18
|
| Pharmaceutical form(s) |
Capsule, hard
|
| Condition(s) / indication(s) |
Treatment of non-small cell lung carcinoma (NSCLC)
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Roche Registration GmbH
Tel. +41 616879411 |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|